Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
Altimmune - 2025/02/19 | Piper Sandler
Altimmune – Investors Overview
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference ...
Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA ...
Altimmune Extends Lonza Partnership To Support Production Of AdCOVID ...
Altimmune Initiates RESTORE Phase 2 Trial for Pemvidutide in Alcohol ...
FinancialContent - How Altimmune Could Grab a Big Chunk of the GLP-1 Market
Altimmune stock soars over 10% premarket on positive mid-stage data for ...
Altimmune se tambalea en bolsa tras revelar datos mixtos de su fármaco ...
Altimmune Relocating Headquarters from Maryland to New Jersey | citybiz
ALT公布其培维肽(pemvidutide)极度乐观的中期结果 Altimmune 公布了针对391名受试者的为期48周的重磅试验性减肥药培维 ...
Why Altimmune Stock is Soaring
Altimmune Lab Portrait 7 | Bethesda Headshots
Altimmune Lab Portrait 14 | Bethesda Headshots
Pemvidutida: el nuevo fármaco de Altimmune que amplía el uso de los ...
Altimmune (ALT) gets FDA Breakthrough Therapy Designation in MASH | ALT ...
#pharma #biotech #obesity #liver #pv100 #pharmavoice100 | Altimmune ...
Altimmune, Inc. on LinkedIn: Altimmune to Participate at Two Upcoming ...
快讯 | Altimmune GLP-1/GCGR双激动剂Pemvidutide临床结果积极 - 知乎
Altimmune Awaits Results Of Fatty Liver Disease Drug Pemvidutide
Altimmune CEO on what’s next for its experimental obesity drug
Altimmune drug pemvidutide shows 58% MASH resolution in Phase 2b | ALT ...
A Closer Look at Altimmune Inc’s Financial Results and Future Prospects ...
Altimmune Reveals Pemvidutide's Effects on Cardioinflammatory Lipids at ...
Altimmune Obesity Drug Provides Class-Leading Lean Mass Preservation ...
Altimmune (ALT) Stock Rises Amid Clinical Trial Progress: What's Going ...
Michael Feigh on LinkedIn: Altimmune Granted Fast Track Designation By ...
Pemvidutide | Altimmune
Altimmune Patents - Insights & Stats
Altimmune leveraging novel intranasal technology in the race against ...
Altimmune (ALT) Stock Soars 27% on Phase 2 Obesity Drug Data - Wealthy ...
Altimmune Initiates RESTORE Phase 2 Trial for Liver Disease Treatment
Altimmune Inc.’s New Price Target Ignites Investor Interest
Altimmune Reports the P-IIb (IMPACT) Trial Data on Pemvidutide for ...
Biotech Firm Altimmune Faces Pivotal Week with Key Financial and ...
Altimmune to be bought out by Eli Lilly? SEC filing underway : r/Altimmune
Altimmune shares slide after $75 million registered direct offering
Altimmune starts public stock-and-warrant offering | ALT Stock News
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics | The ...
BioNews | Altimmune ：公布I期ALT-801针对肥胖及NASH中期积极结果 作者：林出 微信公众号：蹊之美股生物医药 ...
Altimmune nach Goldman-Upgrade: Von Sell auf Neutral – Cash-Sicherheit
Altimmune shares slump as weight-loss drug's fatty liver trial data ...
Altimmune plans Phase 3 MASH trial for second half 2026
Altimmune Stock: On the Rise Again?
Altimmune starts testing long-acting rival to AstraZeneca NASH drug ...
Altimmune Shares Poised for Potential Breakthrough - Stocks Today
Altimmune Outlines Pemvidutide Plans In MASH And Beyond
Altimmune CEO Bill Enright to depart - Washington Business Journal
Securities Lawsuit Risks and Investment Implications for Altimmune (ALT)
Altimmune Boosts Immunotherapy Distribution with Blockchain‑Powered ...
Pemvidutida: el agonista dual de Altimmune en fase de ensayos ...
Altimmune logo in transparent PNG format
Altimmune and University of Alabama announced potent respiratory ...
Altimmune (NASDAQ:ALT): The Next Generation of Weight Loss Treatment ...
Altimmune (ALT) - Revenue
Altimmune completes dosing in the Phase 2 MOMENTUM trial
Altimmune Advances Liver Disease Treatment As Pemvidutide Shows Promise ...
How Altimmune Could Grab a Big Chunk of the GLP-1 Market - Eli Lilly ...
Altimmune Stock Soars Over 10% Premarket On Positive Mid-Stage Data For ...
Why is Altimmune stock falling today?
Shortfinder Short Report on Altimmune - Activ8Insights
Altimmune - Org chart | The Org
Altimmune Stock Quote ALT - Stock Price, News, Charts, Message Board ...
ALT | Altimmune to Present New Data on the Anti-Inflammatory and Anti ...
Healthcare | Piper Sandler
The Case for ALT (Altimmune) : r/Biotechplays
B2i Digital on LinkedIn: We want to welcome Altimmune, Inc. (Nasdaq ...
알티뮨 (ALT) Altimmune, Inc 하락하는 이유 (23.03.21) : 네이버 블로그
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
ONDS Q2 2025 Earnings: EPS Beat & Key Numbers
Altimmune's (ALT) Astounding Journey From $1 To $20 In Just Few Months
#jpm24 #obesity #nash #hepatitisb #jpm2024 | Altimmune, Inc.
Altimmune: Changing Focus To Pemvidutide In 2022 (NASDAQ:ALT) | Seeking ...
Altimmune募资2.025亿美元，推进GLP-1/GCGR激动剂III期开发医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Altimmune, Inc. on LinkedIn: #clinicaltrial #pemvidutide #mash
Altimmune, Inc. on LinkedIn: #clinicaltrial #pemvidutide #obesity #easd2023
Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential
Altimmune, Inc. on LinkedIn: #pemvidutide #glp1 #glucagon #obesity # ...
Altimmune, Inc. (ALT): A Good GLP-1 and Weight Loss Stock to Buy Now?
Altimmune, Inc. 2023 Q3 - Results - Earnings Call Presentation (NASDAQ ...
Altimmune, Inc. on LinkedIn: #firesidechat #obesity #mash
알티뮨, ‘GLP-1/GCG 작용제’ 비만2상 “안전성 논란” - 바이오스펙테이터
Pharma Boom: Altimmune’s Latest Innovation Sparks Excitement
Altimmune, Inc. | LinkedIn
#pemvidutide #nafld #tlm23 | Altimmune, Inc.
Big Changes at Altimmune: A New CEO Steps Up for Future Growth
Altimmune, Inc. on LinkedIn: #pemvidutide #obesity #adascisessions #ada2024
#finance #pharmaceutical #biotech | Altimmune, Inc.
Pemvidutide: a GLP-1/glucagon dual receptor agonist | Altimmune, Inc ...
Altimmune, Inc. on LinkedIn: #metabolic
Optimistic Outlook for Altimmune’s Pemvidutide Despite Phase 2b Setback ...
Altimmune, Inc. posted on LinkedIn
Altimmune’s Pemvidutide Advances: Analyst Recommends Buy with Promising ...
Coulter Partners places seasoned biopharmaceutical industry executives ...
Altimmune's Pemvidutide: A High-Conviction Biotech Play in the Fast ...
Altimmune, Inc. 2025 Q1 - Results - Earnings Call Presentation (NASDAQ ...
48周体重减轻15.6%！Altimmune减肥新药II期研究成功医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Altimmune: Considering If A Repeat Of The 2025 Run-Up Is On Tap (NASDAQ ...
We’re thrilled to welcome Luis Sanay as VP of Investor Relations at ...
Altimmune's Bold Move: Expanding Pemvidutide's Reach to Alcohol-Related ...
Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT ...
@GLP1Signals (@malim27136954) / Posts / X
Altimmune, Inc. (ALT) Gains Analyst Support as Pemvidutide Advances ...
PRISM MARKETVIEW HIGHLIGHTS ALTIMMUNE’S POSITIVE TOPLINE RESULTS IN ...
Altimmune, Inc. (NASDAQ:ALT) Q3 2023 Earnings Call Transcript - Insider ...
Altimmune, Inc. on LinkedIn: #icymi #obesity #mash
Altimmune, Inc. Stock Overview — ALT Summary & Analysis — Roic AI
Novo-Nordisk-Rivale: Hype um Adipositas-Medikamente: Altimmune-Aktie ...
Altimmune’s Conference Momentum: Pivotal Validation for Pemvidutide’s ...
Altimmune: Unlocking the Pharma Puzzle - StocksToTrade
Graviola Amazing: COVID-19 vaccine efficacy and effectiveness—the ...
Altimmune, Inc. (ALT): Why Are Hedge Funds Shorting This ...
Altimmune, Inc. Directory – Maryland Tech Council
Graphic
Biotech Stocks Diverge On New Results For Weight-Loss Drug In MASH ...
